Amoxiclav, 1000 mg+200 mg powder 5 pcs

Pharmacological action – broad spectrum antibacterial, bactericidal.

Pharmacodynamics

The drug Amoxiclav® is a combination of amoxicillin and clavulanic acid.

Amoxicillin is a semisynthetic penicillin (beta-lactam antibiotic) that inhibits one or more enzymes (often referred to as penicillin-binding proteins, PBPs) in the peptidoglycan biosynthesis pathway, which is an integral structural component of the bacterial cell wall. Inhibition of peptidoglycan synthesis leads to loss of cell wall strength, which usually causes lysis and cell death of microorganisms.

Amoxicillin is degraded by the action of beta-lactamases produced by resistant bacteria, so that the spectrum of activity of amoxicillin does not include microorganisms that produce these enzymes.

Clavulanic acid is a beta-lactam that is structurally related to penicillins. It inhibits some beta-lactamases, thereby preventing inactivation of amoxicillin and broadening its spectrum of activity to include bacteria normally resistant to amoxicillin as well as other penicillins and cephalosporins. Clavulanic acid itself has no clinically significant antibacterial activity.

The drug Amoxiclav® has a bactericidal effect in vivo on the following microorganisms:

– Gram-positive aerobes – Staphylococcus aureus*, Streptococcus pneumoniae, Streptococcus pyogenes;

– Gram-negative aerobes – Enterobacter spp.**, Escherichia coli*, Haemophilus influenzae*, species of the genus Klebsiella*, Moraxella catarrhalis* (Branhamella catarrhalis).

The drug Amoxiclav® has a bactericidal effect in vitro against the following microorganisms (but clinical significance is still unknown):

– Gram-positive aerobes – Bacillis anthracis*, species of the genus Corynebacterium, Enterococcus faecalis*, Enterococcus faecium*, Listeria monocytogenes, Nocardia asteroides, coagulazonegative staphylococci* (including Staphylococcus epidermidis), Streptococcus agalactiae, other species of the genus Streptococcus, Streptococcus viridans;

– gram-positive anaerobes – species of the genus Clostridium, species of the genus Peptococcus, species of the genus Peptostreptococcus;

– gram-negative aerobes – Bordetella pertussis, species of the genus Brucella, Gardnerella vaginalis, Helicobacter pylori, species of the genus Legionella, Neisseria gonorrhoeae*, Neisseria meningitidis*, Pasteurella multocida, Proteus mirabilis*, Proteus vulgaris*, species of the genus Salmonella*, species of the genus Shigella*, Vibrio cholerae, Yersinia enterocolitica*;

– gram-negative anaerobes – species of the genus Bacteroides* (including Bacteroides fragilis), species of the genus Fusobacterium*;

– others – Borrelia burgdorferi, Chlamydia spp., Leptospira icterohaemorrhagiae, Treponema pallidum.

* Some strains of these bacterial species produce beta-lactamases, which contributes to their insensitivity to amoxicillin monotherapy.

** Most strains of these bacteria are resistant to the amoxicillin/clavulanic acid combination in vitro, but the clinical effectiveness of this combination has been demonstrated in the treatment of urinary tract infections caused by these strains.

Pharmacokinetics

The main pharmacokinetic parameters of amoxicillin and clavulanic acid are similar. Amoxicillin and clavulanic acid are well soluble in aqueous solutions with physiological pH value and after oral administration of Amoxiclav® are quickly and completely absorbed from the gastrointestinal tract. Absorption of the active substances – amoxicillin and clavulanic acid – is optimal when the drug is taken at the beginning of a meal.

The bioavailability of amoxicillin and clavulanic acid after oral administration is about 70%.

The peak of plasma concentrations is reached approximately 1 hour after ingestion. Values of Cmax for amoxicillin (depending on the dose) are 3-12 mcg/ml, for clavulanic acid – about 2 mcg/ml.

The Cmax in plasma after a bolus injection of 1.2 g (1000+200 mg) of the drug is 105.4 mg/L for amoxicillin and 28.5 mg/L for clavulanic acid.

When using Amoxiclav® plasma concentrations of amoxicillin/clavulanic acid are similar to those when administering orally the corresponding doses of amoxicillin or clavulanic acid separately in equivalent doses.

The two components are characterized by sufficient Vd in various organs, tissues and body fluids (including lungs, abdominal cavity organs; fat, bone and muscle tissues; pleural, synovial and peritoneal fluids; skin, bile, urine, purulent secretions, sputum, interstitial fluid).

The plasma protein binding is moderate – 25% for clavulanic acid and 18% for amoxicillin.

The Vd is approximately 0.3-0.4 L/kg for amoxicillin and approximately 0.2 L/kg for clavulanic acid.

Amoxicillin and clavulanic acid do not penetrate the blood-brain barrier in non-inflamed cerebral membranes.

Amoxicillin (like most penicillins) is excreted with breast milk. Trace amounts of clavulanic acid are also found in breast milk. Amoxicillin and clavulanic acid penetrate the placental barrier.

Amoxicillin is excreted mainly by the kidneys, whereas clavulanic acid is excreted through both renal and extrarenal mechanisms. After a single oral administration of one tablet of 250+125 mg or 500+125 mg, approximately 60-70% of amoxicillin and 40-65% of clavulanic acid are excreted unchanged in the urine during the first 6 h. About 10-25% of the initial dose of amoxicillin is excreted with urine as inactive penicillic acid. Clavulanic acid in humans undergoes intensive metabolism to form 2,5-dihydro-4-(2-hydroxyethyl)-5-oxo-1H-pyrrol-3-carboxylic acid and 1-amino-4-hydroxy-butane-2-one and is excreted with urine and feces.

The average T1/2 of amoxicillin/clavulanic acid is approximately 1 h, the average total clearance is approximately 25 L/h in healthy patients. Various studies have found that urinary excretion of amoxicillin within 24 h is approximately 50-85%, clavulanic acid 27-60%. The greatest amount of clavulanic acid is excreted during the first 2 hours after intake.

Patients with impaired liver function

In patients with severe renal impairment the T1/2 is increased to 7.5 h for amoxicillin and to 4.5 h for clavulanic acid.

In patients with hepatic impairment the dose of the drug should be adjusted with caution: constant monitoring of the liver condition is necessary.

The two components are eliminated by hemodialysis and minor amounts by peritoneal dialysis.

Indications

Infections caused by susceptible strains of microorganisms:

– Upper respiratory tract and ENT (including acute and chronic sinusitis, acute and chronic otitis media, tonsillitis, pharyngitis);

– Lower respiratory tract (including acute bronchitis with bacterial superinfection, chronic bronchitis, pneumonia);

– urinary tract (e.g. cystitis, urethritis, pyelonephritis);

– in gynecology;

Active ingredient

Composition

1 vial of lyophilized powder contains:

The active ingredients: amoxicillin (as sodium salt) 1000 mg and clavulanic acid (as potassium salt) 200 mg.

How to take, the dosage

V/v.

In children: with body weight less than 40 kg – the dose is calculated depending on the body weight.

Lower than 3 months with body weight less than 4 kg – 30 mg/kg (in terms of the entire drug Amoxiclav®) every 12 hours.

Lower than 3 months with body weight more than 4 kg – 30 mg/kg (in terms of the entire drug Amoxiclav®) every 8 hours.

In children younger than 3 months Amoxiclav® should be administered only slowly by infusion during 30-40 minutes.

In children from 3 months to 12 years of age – 30 mg/kg (in terms of the entire drug Amoxiclav®) at 8-hour intervals, in case of severe course of infection – at 6-hour intervals.

In children with impaired renal function

Dose adjustment is based on the maximum recommended dose of amoxicillin. In patients with creatinine Cl values above 30 ml/min, dose adjustment is not necessary.

Each 30 mg of Amoxiclav® contains 25 mg of amoxicillin and 5 mg of clavulanic acid.

Adults and children over 12 years of age or weighing more than 40 kg – 1.2 g of the drug (1000+200 mg) at 8-hour intervals, in case of severe course of infection – at 6-hour intervals.

Prophylactic doses in surgical interventions: 1.2 g in induction anesthesia (in case of duration of surgery less than 2 hours). For longer operations 1.2 g up to 4 times during the day.

In patients with renal insufficiency the dose and/or interval between injections of the drug should be adjusted according to the degree of insufficiency.

As 85% of the drug is removed by hemodialysis, the usual dose of Amoxiclav® should be given at the end of each hemodialysis procedure. No dose adjustment is required for peritoneal dialysis.

The course of treatment is 5-14 days. The duration of treatment is determined by the attending physician. When the severity of symptoms decreases, switching to oral forms of Amoxiclav® is recommended for continuation of therapy.

Preparation of solutions for intravenous injections. Dissolve the contents of the bottle in water for injection: 600 mg (500+100 mg) in 10 ml of water for injection or 1.2 g (1000+200 mg) in 20 ml of water for injection. I/V injected slowly (over 3-4 minutes).

The drug Amoxiclav® should be administered within 20 minutes after preparation of solutions for IV administration.

Preparation of solutions for intravenous infusion. For infusion of Amoxiclav® a further dilution is necessary: prepared solutions containing 600 mg (500 + 100 mg) or 1.2 g (1000 + 200 mg) of the drug should be diluted in 50 or 100 ml of infusion solution, respectively. The duration of infusion is 30-40 minutes.

The solution of Amoxiclav® should not be mixed with solutions of dextrose, dextran or sodium bicarbonate.

Only clear solutions should be used. Prepared solutions should not be frozen.

Amoxiclav® Quicktab

Internal. Regimen of dosing is adjusted individually depending on patient’s age, body weight, renal function and severity of infection.

The pills should be dissolved in half a cup of water (30 ml minimum) and stirred thoroughly; then the pills should be drunk or held in the mouth until completely dissolved, and then swallowed.

In order to reduce the risk of gastrointestinal side effects, the drug should be taken at the beginning of a meal.

Dispersible tablets of Amoxiclav® Quicktab 500 mg/125 mg:

Adults and children over 12 years of age with a body weight of ?40 kg

To treat mild to moderate infections, 1 tablet (500 mg/125 mg) every 12 hours (2 times daily).

To treat severe infections and respiratory infections, 1 tablet (500 mg/125 mg) every 8 hours (3 times daily).

The maximum daily dose of Amoxiclav® Quicktab is 1500 mg amoxicillin/375 mg clavulanic acid.

Patients with impaired renal function. In patients with creatinine Cl above 30 ml/min there is no need to adjust the dose.

Interaction

For all dosage forms

Antacids, glucosamine, laxatives, aminoglycosides slow absorption, ascorbic acid increases absorption.

Diuretics, allopurinol, phenylbutazone, NSAIDs and other drugs that block tubular secretion (probenecid) increase the concentration of amoxicillin (clavulanic acid is eliminated mainly by glomerular filtration).

The concomitant use of Amoxiclav® and methotrexate increases the toxicity of methotrexate.

The co-administration with allopurinol increases the incidence of exanthema. Concomitant use with disulfiram should be avoided.

Decreases the effectiveness of drugs in the metabolism of which PABA is formed; ethinyl estradiol – risk of breakthrough bleeding.

The literature describes rare cases of increased INR in patients when coadministering acenocoumarol or warfarin and amoxicillin. If concomitant use with anticoagulants is necessary, PV or INR should be closely monitored when prescribing or withdrawing the drug.

The combination with rifampicin is antagonistic (mutual weakening of the antibacterial effect). The preparation Amoxiclav® should not be used simultaneously in combination with bacteriostatic antibiotics (macrolides, tetracyclines), sulfonamides because of possible decrease of effectiveness of Amoxiclav® preparation.

The drug Amoxiclav® reduces the effectiveness of oral contraceptives.

For the powder for preparation of solution for intravenous administration additionally

The drug Amoxiclav® and aminoglycoside antibiotics are chemically incompatible.

The drug Amoxiclav® should not be mixed in a syringe or infusion bottle with other drugs.

Avoid mixing with solutions of dextrose, dextran, sodium bicarbonate, as well as with solutions containing blood, proteins, lipids.

Special Instructions

For all dosage forms

Hematopoietic, hepatic and renal function should be monitored during course treatment.

In patients with severe renal dysfunction, adequate dose adjustment or increased intervals between doses is required.

The development of superinfection due to growth of microflora insensitive to it is possible, which requires appropriate change in antibiotic therapy.

In patients who are hypersensitive to penicillins, cross-allergic reactions with cephalosporin antibiotics are possible.

In women with premature rupture of fetal membranes, it has been found that prophylactic therapy with amoxicillin + clavulanic acid may be associated with an increased risk of necrotizing colitis in the newborn.

In patients with decreased diuresis, crystalluria is very rare. During the use of high doses of amoxicillin, it is recommended to take sufficient fluids and maintain adequate diuresis to reduce the likelihood of amoxicillin crystal formation.

Laboratory tests. High concentrations of amoxicillin give a false positive reaction for urine glucose when using Benedict’s reagent or Fehling’s solution. Enzymatic reactions with glucosidase are recommended.

Amoxicillin and clavulanic acid may cause non-specific binding of immunoglobulins and albumin to the erythrocyte membrane, which may cause a false positive Coombs test.

Information for patients on a low-sodium diet: Each bottle of 600 mg (500+100 mg) contains 29.7 mg of sodium. Each 1.2 g (1000+200 mg) bottle contains 59.3 mg of sodium. The amount of sodium in the maximum daily dose exceeds 200 mg.

Contraindications

– hypersensitivity to the components of the drug;

– hypersensitivity to penicillins, cephalosporins and other beta-lactam antibiotics in the history;

– cholestatic jaundice and/or other liver dysfunction caused by taking amoxicillin/clavulanic acid, in the history;

– infectious mononucleosis and lympholeukemia.

Side effects

Amoxiclav® film-coated tablets and powder for preparation of solution for IV administration

Digestive system disorders: loss of appetite, nausea, vomiting, diarrhea, abdominal pain, gastritis, stomatitis, glossitis, black “hairy” tongue, darkening of tooth enamel, hemorrhagic colitis (may also develop after therapy), enterocolitis, pseudomembranous colitis, liver dysfunction, increased ALT, AST, ALP activity and/or bilirubin level in blood plasma, liver failure (more common in the elderly, men, with long-term therapy), cholestatic jaundice, hepatitis.

Allergic reactions: itching, urticaria, erythematous rash, erythema multiforme, angioedema, anaphylactic shock, allergic vasculitis, exfoliative dermatitis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, syndrome similar to serum sickness, toxic epidermal necrolysis.

Hematopoietic and lymphatic system disorders: reversible leukopenia (including neutropenia), thrombocytopenia, hemolytic anemia, reversible increase in PV (when combined with anticoagulants), reversible increase in bleeding time, eosinophilia, pancytopenia, thrombocytosis, agranulocytosis.

CNS disorders: dizziness, headache, seizures (may occur in patients with impaired renal function when taking high doses of the drug).

Urinary system disorders: interstitial nephritis, crystalluria, hematuria.

Others: candidiasis and other types of superinfections.

Amoxiclav®

For film-coated tablets, powder for preparation of suspension for oral administration, powder for preparation of solution for injection additionally

CNS side: hyperactivity. Feeling of anxiety, insomnia, behavioral changes, agitation.

Amoxiclav®

Amoxiclav® Quicktab

. Amoxiclav® Quicktab and Amoxiclav® powder for preparation of suspension for oral administration

Hematopoietic and lymphatic system disorders: rare – reversible leukopenia (including neutropenia), thrombocytopenia; very rare – eosinophilia, thrombocytosis, reversible agranulocytosis, increased bleeding time and reversible increase in PV, anemia, including.including reversible hemolytic anemia.

Immune system disorders: frequency unknown – angioneurotic edema, anaphylactic reactions, allergic vasculitis, syndrome similar to serum sickness.

Nervous system disorders: infrequent – dizziness, headache; very rare – insomnia, agitation, anxiety, behavioral changes, reversible hyperactivity, seizures; seizures may be observed in patients with impaired renal function and those receiving high doses of the drug.

Gastrointestinal disorders: often – loss of appetite, nausea, vomiting, diarrhea. Nausea is more often observed when high doses are taken orally. If gastrointestinal disorders are confirmed, they can be eliminated if the drug is taken at the beginning of a meal; infrequently – indigestion; very rare – antibiotic-associated colitis induced by taking antibiotics (including pseudomembranous and hemorrhagic colitis), black “hairy” tongue, gastritis, stomatitis. Children have very rarely seen discoloration of the surface layer of tooth enamel. Oral care can help prevent discoloration of tooth enamel.

Skin disorders: infrequent – skin rash, pruritus, urticaria; rare – erythema multiforme exudative; frequency unknown – Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous exfoliative dermatitis, acute generalized exanthematous pustulosis.

Urinary system disorders: very rarely – crystalluria, interstitial nephritis, hematuria.

Hepatic and biliary tract disorders: infrequent – increase of ALT and/or AST activity (this phenomenon is observed in patients treated with beta-lactam antibiotics, but its clinical significance is unknown); Undesired liver disorders were observed mostly in men and elderly patients and may be associated with long-term therapy. These adverse events are very rarely seen in children.

The signs and symptoms listed usually occur during or immediately after completion of therapy, but in some cases may not occur for several weeks after completion of therapy. The adverse events are generally reversible. Liver adverse events can be severe, and in exceptionally rare cases deaths have been reported. In almost all cases these were patients with severe comorbidities or patients receiving concomitant potentially hepatotoxic drugs. Very rarely – increased ALP activity, elevated bilirubin levels, hepatitis, cholestatic jaundice (noted with concomitant therapy with other penicillins and cephalosporins).

Others: frequent – candidiasis of the skin and mucous membranes; frequency unknown – growth of insensitive microorganisms.

Overdose

There have been no reports of death or life-threatening side effects due to overdose of the drug.

Symptoms: in most cases – gastrointestinal disorders (abdominal pain, diarrhea, vomiting), possibly also anxiety, insomnia, dizziness, in single cases – seizures.

Treatment: In case of overdose the patient must be under medical supervision; treatment is symptomatic.

In case of recent intake (less than 4 hours) of the drug it is necessary to perform gastric lavage and prescribe activated charcoal to reduce absorption. Amoxicillin/clavulanate potassium is removed by hemodialysis.

Pregnancy use

In pregnancy and lactation, Amoxiclav® is used only if the estimated benefit to the mother exceeds the potential risk to the fetus and child.

Amoxiclav® Quicktab can be administered during pregnancy in the presence of clear indications.

Amoxicillin and clavulanic acid penetrate into breast milk in small amounts.

Similarities